Exclusive: Microsoft, Sam Altman back a new AI biotech upstart
Most artificial intelligence biotechs start with a computer scientist or two and an algorithm. Jen Nwankwo started from the other side of the spectrum.
She had just gotten her PhD from Tufts in 2016, a dyed-in-the-wool pharmacologist who had received an HHMI fellowship and worked on sickle cell drug discovery at Boston Children’s Hospital, and was working at Bain Capital when she started reading up on artificial intelligence. She’d pour over every news article she saw on self-driving cars or image recognition, wondering with each word how she could apply the same technology to the problems that plagued her as a drug developer.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters